Literature DB >> 16267500

Genetic background of HSH in three Polish families and a patient with an X;9 translocation.

Reetta Jalkanen1, Ewa Pronicka, Henna Tyynismaa, Andre Hanauer, Roxanne Walder, Tiina Alitalo.   

Abstract

Hypomagnesemia with secondary hypocalcemia (HSH) is a rare inherited disease, characterised by neurological symptoms, such as tetany, muscle spasms and seizures, due to hypocalcemia. It has been suggested that HSH is genetically heterogeneous, but only one causative gene, TRPM6, on chromosome 9 has so far been isolated. We have now studied the genetic background of HSH in four Polish patients belonging to three families, and a HSH patient carrying an apparently balanced X;9 translocation. The translocation patient has long been considered as an example of the X-linked form of HSH. We identified six TRPM6 gene mutations, of which five were novel, in the Polish patients. All the alterations were either nonsense/splicing or missense mutations. The clinical picture of the patients was similar to the HSH patients reported earlier. No genotype-phenotype correlation could be detected. Sequencing did not reveal any TRPM6 or TRPM7 gene mutations in the female HSH patient with an X;9 translocation. Isolation of the translocation breakpoint showed that the chromosome 9 specific breakpoint mapped within satellite III repeat sequence. The X-chromosomal breakpoint was localised to the first intron of the vascular endothelial growth factor gene, VEGFD. No other sequence alterations were observed within the VEGFD gene. Even though the VEGFD gene was interrupted by the X;9 translocation, it seems unlikely that VEGFD is causing the translocation patient's HSH-like phenotype. Furthermore, re-evaluation of patient's clinical symptoms suggests that she did not have a typical HSH.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16267500     DOI: 10.1038/sj.ejhg.5201515

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  6 in total

1.  Mice defective in Trpm6 show embryonic mortality and neural tube defects.

Authors:  Roxanne Y Walder; Baoli Yang; John B Stokes; Patricia A Kirby; Xiao Cao; Peijun Shi; Charles C Searby; Russell F Husted; Val C Sheffield
Journal:  Hum Mol Genet       Date:  2009-08-18       Impact factor: 6.150

2.  New TRPM6 missense mutations linked to hypomagnesemia with secondary hypocalcemia.

Authors:  Sergio Lainez; Karl Peter Schlingmann; Jenny van der Wijst; Bernd Dworniczak; Femke van Zeeland; Martin Konrad; René J Bindels; Joost G Hoenderop
Journal:  Eur J Hum Genet       Date:  2013-08-14       Impact factor: 4.246

3.  Hypomagnesemia and functional hypoparathyroidism due to novel mutations in the Mg-channel TRPM6.

Authors:  Marianne C Astor; Kristian Løvås; Anette S B Wolff; Bjørn Nedrebø; Eirik Bratland; Jon Steen-Johnsen; Eystein S Husebye
Journal:  Endocr Connect       Date:  2015-08-13       Impact factor: 3.335

4.  Case Report: Investigation and molecular genetic diagnosis of familial hypomagnesaemia: a case report.

Authors:  Jamie Willows; Maryam Al Badi; Chloe Richardson; Noel Edwards; Sarah Rice; John A Sayer
Journal:  F1000Res       Date:  2019-05-15

5.  Case Report: Novel TRPM6 Mutations Cause Hereditary Hypomagnesemia With Secondary Hypocalcemia in a Chinese Family and a Literature Review.

Authors:  Yiran Han; Yajuan Zhao; Hua Wang; Liang Huo
Journal:  Front Pediatr       Date:  2022-07-12       Impact factor: 3.569

6.  Novel Alleles of gon-2, a C. elegans Ortholog of Mammalian TRPM6 and TRPM7, Obtained by Genetic Reversion Screens.

Authors:  Eric J Lambie; Robert D Bruce; Jeffrey Zielich; Sonia N Yuen
Journal:  PLoS One       Date:  2015-11-25       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.